Lv44
690 积分 2024-06-13 加入
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
2天前
已完结
A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity
2天前
已关闭
Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
2天前
已完结
The other side of the incretin story: GIPR signaling in energy homeostasis
2天前
已完结
Understanding the activation mechanism of GLP-1R/GIPR by dual agonist Tirzepatide via molecular dynamics and protein-peptide binding
2天前
已完结
Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects
2天前
已完结
Unravelling the GIPR agonist versus antagonist paradox
2天前
已完结
Long-Acting and Stapled GLP-1R/GIPR/GCGR Triple Agonist for the Treatment of Obesity and Atherosclerosis
2天前
已完结
Proline Analogues in Drug Design: Current Trends and Future Prospects
1个月前
已完结
Preparation of ( S )‐ N ‐Boc‐5‐oxaproline
1个月前
已完结
皖公网安备34019202002308
